Evaluation of Sleep Quality in Head and Neck Cancer Patients Throughout Treatment Course
Key facts
- Who runs it
- Thomas Jefferson University
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 1 Jan 2022
- Ended
- 1 Dec 2025
- Type of study
- Observational
- Treatments tested
- Survey Administration
- Record updated
- 29 September 2025
- Why it stopped
- PI agreed to close study as prompted by PRMC inquiry
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Males and females
- Adult at least 18 years old
- Capable of giving informed consent
- Diagnosed with head and neck cancer (previously untreated, any stage)
- Treatment plan involves surgery
- Willing to comply with all study procedures and be available for the duration of the study
- English-speaking
Who cannot take part
- Pre-existing sleep disorder defined below:; Obstructive sleep apnea; Insomnia; Narcolepsy; Restless leg syndrome; Rapid eye movement (REM) sleep behavior disorder
- Non-English speaking
Where in United States
- Thomas Jefferson University HospitalPhiladelphia, United StatesNo longer taking part
About the trial
What the trial wants to find out
This study examines how head and neck cancer treatment affects quality of sleep over time and factors that contribute to sleep quality. Sleep plays a critical role in healing and quality of life, and recent studies investigating sleep disorders in head and neck cancer patients reveal sleep quality is a major determinant of post-treatment outcomes. Information from this study may help researchers better understand how treatment impacts sleep quality so that they can make changes that may help improve patient sleep quality.
The group in the trial
- Observational (survey)
COHORT 1-TP1: Patients complete surveys over 20 minutes on post-op day 3 and on day of discharge (or within 1 week). COHORT 1-TP2: Patients complete surveys over 15 minutes at all regularly scheduled follow-up appointments (approximately 1 month, 3 months, 6 months, 12 months). COHORT 2: Patients complete surveys over 15 minutes once.
Treatment: Survey Administration
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 29 September 2025